Benzinga | Sep 11, 2020 09:17AM EDT

Adams Pharma Highlights Presentation Of Post-Hoc Data Analysis For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At 2020 Movement Disorder Society Virtual Congress

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI(r) (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

"These presentations provide further evidence that GOCOVRI may reduce OFF time for people with Parkinson's, with prolonged effects for at least two years," said Jean Hubble MD, Vice President, Medical Affairs at Adamas. "Both dyskinesia and OFF disrupt daily activities for people with PD and treating dyskinesia should not come at the expense of increased OFF, or vice versa. For patients who seek good ON time with long-term reductions in dyskinesia and OFF, providers can consider GOCOVRI as a treatment option shown to provide substantial and sustained benefits."

The following posters will be available in the MDS 2020 Virtual Poster Hall beginning September 11, 2020:

Poster #896: Among Parkinson's disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials

Lead Author: Robert A. Hauser, MD, MBA, USF Parkinson's Disease and Movement Disorders Center, Parkinson Foundation Center of Excellence.

Poster #955: Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson's disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

Lead Author: Caroline M. Tanner, MD, PhD, University of California San Francisco.